1 Table of Contents 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 12 2.1 Therapy Area Overview 12 2.1.1 Rheumatoid Arthritis 12 2.1.2 Osteoarthritis 13 2.1.3 Osteoporosis 14 2.1.4 Systemic Lupus Erythematosus 15 2.1.5 Psoriatic Arthritis 16 2.2 Etiology 17 2.3 Pathophysiology 19 2.3.1 Rheumatoid Arthritis 19 2.3.2 Osteoarthritis 20 2.3.3 Osteoporosis 20 2.3.4 Systemic Lupus Erythematosus 21 2.3.5 Psoriatic Arthritis 22 2.4 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 23 2.4.1 Rheumatoid Arthritis 24 2.4.2 Osteoarthritis 25 2.4.3 Osteoporosis 26 2.4.4 Systemic Lupus Erythematosus 27 2.4.5 Psoriatic arthritis 28 2.5 Treatment 29 2.5.1 Rheumatoid Arthritis 29 2.5.2 Osteoarthritis 31 2.5.3 Osteoporosis 32 2.5.4 Systemic Lupus Erythematosus 35 2.5.5 Psoriatic Arthritis 37 3 Key Marketed Products 40 3.1 Overview 40 3.2 Humira (adalimumab) - AbbVie 41 3.3 Enbrel (etanercept) - Amgen 44 3.4 Simponi (golimumab) - Johnson & Johnson 46 3.5 Remicade (infliximab) - Johnson & Johnson 48 3.6 Rituxan (rituximab) - Roche 51 3.7 Stelara (ustekinumab) - Johnson & Johnson 52 3.8 Cosentyx (secukinumab) - Novartis 54 3.9 Prolia (denosumab) - Amgen 55 3.10 Orencia (abatacept) - Bristol-Myers Squibb 57 3.11 Actemra (tocilizumab) - Roche 59 3.12 Benlysta (belimumab) - GlaxoSmithKline 60 3.13 Forteo (teriparatide) - Eli Lilly 62 4 Pipeline Landscape Assessment 64 4.1 Overview 64 4.2 Pipeline Development Landscape 64 4.3 Molecule Types in the Pipeline 67 4.4 Molecular Targets in the Pipeline 68 4.5 Clinical Trials Landscape 70 4.5.1 Clinical Trial Failure Rates 70 4.5.2 Clinical Trial Duration 73 4.5.3 Clinical Trial Size 77 4.5.4 Cumulative Clinical Program Size 81 4.6 Assessment of Key Pipeline Products 85 4.6.1 Upadacitinib tartrate - AbbVie 85 4.6.2 Filgotinib - Gilead Sciences 86 4.6.3 Lenabasum - Corbus Pharmaceuticals 88 4.6.4 Evenity (romosozumab) - Amgen / UCB / Astellas 89 4.6.5 Avacopan - ChemoCentryx 90 4.6.6 Pegadricase - Selecta Biosciences 92 4.6.7 Anifrolumab - AstraZeneca 94 5 Multi-scenario Market Forecast to 2024 96 5.1 Overall Market Size 96 5.2 Generic Penetration 99 5.3 Revenue Forecast by Molecular Target 101 5.3.1 Products Acting on Tumor Necrosis Factor-Alpha 101 5.3.2 Products Acting on Interleukins and Interleukin Receptors 102 5.3.3 Products Acting on Protein Kinases 103 5.3.4 Products Acting on Cell Surface Antigens 104 5.3.5 Products Acting on Hormones and Hormone Receptors 105 6 Company Analysis and Positioning 107 6.1 Revenue and Market Share Analysis by Company 109 6.1.1 AbbVie 117 6.1.2 Amgen 118 6.1.3 Johnson & Johnson 119 6.1.4 Novartis 120 6.1.5 Pfizer 122 6.1.6 Roche 124 6.1.7 Eli Lilly 125 6.1.8 Bristol-Myers Squibb 126 6.2 Company Landscape 127 6.3 Marketed and Pipeline Portfolio Analysis 129 7 Strategic Consolidations 131 7.1 Licensing Deals 131 7.1.1 Deals by Region, Year and Value 131 7.1.2 Deals by Indication and Value 133 7.1.3 Deals by Stage of Development and Value 134 7.1.4 Deals by Molecule Type, Molecular Target and Value 135 7.1.5 Licensing Deals with Disclosed Values 136 7.2 Co-development Deals 142 7.2.1 Deals by Region, Year and Value 142 7.2.2 Deals by Indication and Value 143 7.2.3 Deals by Stage of Development and Value 144 7.2.4 Deals by Molecule Type, Molecular Target and Value 145 7.2.5 Co-development Deals with Disclosed Values 146 8 Appendix 149 8.1 References 149 8.2 Figures of All Clinical Stage Pipeline Products 162 8.3 Abbreviations 176 8.4 Disease List 177 8.5 Methodology 177 8.5.1 Coverage 178 8.5.2 Secondary Research 178 8.5.3 Market Size and Revenue Forecasts 178 8.5.4 Pipeline Analysis 179 8.5.5 Competitive Landscape 179 8.6 Contact Us 179 8.7 Disclaimer 180

1.1 List of Tables Table 1: Rheumatic Disorders Drugs Market, Global, Etiology of RA, OA, Osteoporosis, SLE and PsA, 2018 17 Table 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology of Key Rheumatic Disorders Indications, 2018 23 Table 3: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within RA, 2018 30 Table 4: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for RA, 2018 31 Table 5: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within OA, 2018 32 Table 6: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for OA, 2018 32 Table 7: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within Osteoporosis, 2018 34 Table 8: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for Osteoporosis, 2018 34 Table 9: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within SLE, 2018 36 Table 10: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for SLE, 2018 37 Table 11: Rheumatic Disorders Drugs Market, Global, Overview of the Treatments for Different Patient Segments within PsA, 2018 38 Table 12: Rheumatic Disorders Drugs Market, Global, Off-label Treatments for PsA, 2018 39 Table 13:Rheumatic Disorders Drugs Market, Global, Key Marketed Products Overview, 2018 40 Table 14: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Humira, 2018 41 Table 15: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Enbrel, 2018 44 Table 16: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Simponi, 2018 46 Table 17: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Remicade, 2018 48 Table 18: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Rituxan, 2018 51 Table 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Stelara, 2018 52 Table 20: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Cosentyx, 2018 54 Table 21: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Prolia, 2018 55 Table 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Orencia, 2018 57 Table 23: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Actemra, 2018 59 Table 24: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Indications that have been Approved or are in Late-Stage Development for Benlysta, 2018 60 Table 25: Rheumatic Disorders Drugs Market, Global, Approved Rheumatic Disorders Indications for Forteo, 2018 62 Table 26: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2017-2024 97 Table 27: Rheumatic Disorders Drugs Market, Global, Use of Generics Across Key Indications, 2018 100 Table 28: Rheumatic Disorders Drugs Market, Global, Forecast Revenue by Company (%), 2017-2024 1091.2 List of Figures Figure 1: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2017-2024 24 Figure 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoarthritis, 2017-2024 25 Figure 3: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoporosis, 2017-2022 26 Figure 4: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Systemic Lupus Erythematosus, 2017-2024 27 Figure 5: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Psoriatic Arthritis, 2017-2024 28 Figure 6: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Humira ($bn), 2006-2024 43 Figure 7: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006-2024 45 Figure 8: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010-2024 47 Figure 9: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006-2024 50 Figure 10: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024 52 Figure 11: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Stelara ($bn), 2010-2024 53 Figure 12: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015-2024 55 Figure 13: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Prolia ($bn), 2010-2024 56 Figure 14: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Orencia ($bn), 2014-2023 58 Figure 15: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Actemra ($bn), 2016-2024 60 Figure 16: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Benlysta ($m), 2011-2024 61 Figure 17: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Forteo ($bn), 2006-2024 63 Figure 18: Rheumatic Disorders Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 64 Figure 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Stage of Development, Molecule Type and Program Type, 2018 65 Figure 20: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Stage of Development, 2018 66 Figure 21: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecule Type, 2018 67 Figure 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Molecular Target, 2018 68 Figure 23: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecular Target, 2018 69 Figure 24: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Attrition Rate by Stage of Development (%), 2006-2018 70 Figure 25: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006-2018 71 Figure 26: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006-2018 72 Figure 27: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006-2018 73 Figure 28: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 73 Figure 29: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006-2018 74 Figure 30: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2018 75 Figure 31: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2018 76 Figure 32: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 77 Figure 33: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006-2018 78 Figure 34: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006-2018 79 Figure 35: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006-2018 80 Figure 36: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 81 Figure 37: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006-2018 82 Figure 38: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2018 83 Figure 39: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2018 84 Figure 40: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Upadacitinib tartrate ($bn), 2019-2024 86 Figure 41: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Filgotinib ($bn), 2019-2024 87 Figure 42: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Lenabasum ($bn), 2021-2024 88 Figure 43: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Evenity (romosozumab) ($m), 2019-2024 90 Figure 44: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Avacopan ($m), 2021-2024 92 Figure 45: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Pegadricase ($m), 2020-2024 93 Figure 46: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Anifrolumab ($m), 2019-2024 95 Figure 47: Rheumatic Disorders Drugs Market, Global, Market Size ($bn), 2017-2024 96 Figure 48: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024 99 Figure 49: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF-α ($bn), 2017-2024 102 Figure 50: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins and Interleukin Receptors ($bn), 2017-2024 103 Figure 51: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Protein Kinases ($bn), 2017-2024 104 Figure 52: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Targeting Cell Surface Antigens ($bn), 2017-2024 105 Figure 53: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Hormone Receptors ($bn), 2017-2024 106 Figure 54: Rheumatic Disorders Drugs Market, Global, Company Analysis Matrix, 2017-2024 107 Figure 55: Rheumatic Disorders Drugs Market, Global, Cluster by Growth and Market Share, 2017-2024 108 Figure 56: Rheumatic Disorders Drugs Market, Global, Forecast Market Share by Company (%), 2017-2024 113 Figure 57: Rheumatic Disorders Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024 115 Figure 58: Rheumatic Disorders Market, Global, Revenues by Route of Acquisition, 2017-2024 116 Figure 59: Rheumatic Disorders Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2017-2024 118 Figure 60: Rheumatic Disorders Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017-2024 119